Sarcoidosis: social predictors of severity at presentation

Rabin, David L.; Thompson, Bruce; Brown, Kathleen M.; Judson, Marc A.; Huang, Xiaoxi; Lackland, Daniel T.; Knatterud, Genell L.; Yeager, Henry; Rose, Cecile S.; Steimel, Joanne

doi:10.1183/09031936.04.00070503

Cited by 81 publications

(66 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, in general, patients with a high socioeconomic status reported a better health status. The same conclusion was drawn using data from A Case-Control Etiologic Study of Sarcoidosis (ACCESS) [61].…”

Section: Health Status In Sarcoidosismentioning

confidence: 53%

Fatigue, quality of life and health status in sarcoidosis

Vries

2005

Sarcoidosis

View full text Add to dashboard Cite

Section: Health Status In Sarcoidosismentioning

confidence: 53%

Fatigue, quality of life and health status in sarcoidosis

Vries

2005

Sarcoidosis

View full text Add to dashboard Cite

“…Older individuals were more likely to have severe disease by both measures. In conclusion, it was found that low income and other financial barriers to care are significantly associated with Sarcoidosis severity at presentation even after adjusting for demographic characteristics of race, sex, and age [56].…”

Section: Sarcoidosismentioning

confidence: 97%

“…To confirm the previous study Rabin et al [56] set out to determine sarcoidosis disease severity at first presentation. The results of the study showed that lower income, the absence of private or Medicare health insurance were associ-www.journals.viamedica.pl ↓ SES is associated more severe disease at presentation SES -socioeconomic status ated with sarcoidosis severity at presentation, as were race, sex, and age.…”

Section: Sarcoidosismentioning

confidence: 99%

Socioeconomic Status and Its Relationship to Chronic Respiratory Disease

Sahni

Talwar

Khanijo

et al. 2017

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Socioeconomic status (SES) is defined as an individual's social or economic standing, and is a measure of an individual's or family's social or economic position or rank in a social group. It is a composite of several measures including income, education, occupation, location of residence or housing. Studies have found a lower SES has been linked to disproportionate access to health care in many diseases. There is emerging data in pulmonary diseases such as COPD, asthma, cystic fibrosis, pulmonary hypertension and other chronic respiratory conditions that allude to a similar observation noted in other chronic diseases. In the setting of COPD, SES has an inverse relationship with COPD prevalence, mortality, health utilization costs and HRQoL. Asthma and cystic fibrosis show an increased severity and hospitalizations in relationship to a lower SES. Similar observations were seen in sarcoidosis, PHTN and obstructive sleep apnea. There remains a limited data on non-CF bronchiectasis and interstitial lung diseases. Population SES may be gauged by various measures such as education, occupation, marital status but no value is more indicative than income. Currently guidelines and management algorithms do not factor the effect of SES in the disease process. Despite the great amount of data available, a standardized method must be created to include SES in the prognostic calculations and management of chronic pulmonary diseases.

show abstract

“…Multiple studies show that sarcoidosis tends to be more severe in black patients, whereas, white patients are more likely to have spontaneous resolution. [23,24] Japanese patients have a higher prevalence of cardiac and ocular disease than Western populations. [8] Last, lower socioeconomic status has been associated with more severe disease and new organ involvement.…”

Section: Morbiditymentioning

confidence: 99%

Morbidity and mortality in sarcoidosis

Gerke

2014

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of Review Chronic sarcoidosis is a complex disease with numerous comorbid conditions and can be fatal in some cases. Recognizing causes of morbidity and mortality is important to effectively select treatments, manage symptoms, and improve outcomes. The purpose of this review is to examine emerging knowledge on morbidity and mortality in sarcoidosis. Recent Findings Approximately one to five percent of patients with sarcoidosis die from complications of sarcoidosis. Recent population studies indicate that mortality may be increasing over the past decade. The reasons behind these trends are unclear, but could include increasing incidence, detection rates, severity of disease, or age of the population. Morbidity of sarcoidosis is reflected by a trend of increased hospitalizations over recent years and increased use of healthcare resources. Morbidity can be caused by organ damage from granulomatous inflammation, treatment complications, and psychosocial effects of the disease. Recent studies are focused on morbidity related to cardiopulmonary complications, bone health, and aging within the sarcoidosis population. Last, sarcoidosis is associated with autoimmune diseases, pulmonary embolism, and malignancy; however, the underlying mechanisms linking diseases continue to be debated. Summary Morbidity in sarcoidosis is significant and multifactorial. Mortality is infrequent, but may be increasing over the years.

show abstract

Sarcoidosis: social predictors of severity at presentation

Cited by 81 publications

References 26 publications

Fatigue, quality of life and health status in sarcoidosis

Fatigue, quality of life and health status in sarcoidosis

Socioeconomic Status and Its Relationship to Chronic Respiratory Disease

Morbidity and mortality in sarcoidosis

Contact Info

Product

Resources

About